Does cardiac troponin measurement predict all-cause mortality and cardiotoxicity in asymptomatic cancer patients?
Cardiac troponin measurement is a valuable tool for risk stratification and predicting cardiotoxicity in asymptomatic cancer patients before treatment.
Recent data support the predictive value of cardiac biomarker for all-cause mortality and cardiotoxicity in cancer patients. This review gives an overview about the current literature about cardiac troponins in prediction and identification of high-risk cancer patients. The overview is focusing on diagnostic challenges, biomarker significance, and gaps of knowledge. Latest publications highlight the relevance of cardiac troponin in risk analysis before cancer treatment as well as a potential diagnostic gatekeeper for further cardiological diagnostics and therapy.
Romann et al. (Tue,) studied this question.